Roland Andersson - PAREXEL International Senior Vice President - Clinical Research Services

Mr. Roland Andersson, Ph.D., is Senior Vice President, Clinical Research Services of the Company. In this position, he is responsible for the management of the Companys Phase IIIII client relationships on a global basis, including strategic accounts and the Companys Biopharm Unit, and also oversees the Companys Japanese operations. From February 2011 to February 2014, Dr. Andersson served as Managing Director at Accenture, a consulting company. From April 2010 to February 2011, he was a Partner with Back Bay Life Science Advisors, a life sciences consulting firm. From August 2003 to April 2010 he served as Senior Managing Director at Leerink Swann LLC, an investment bank
Age: 52  President Since 2014      
781 487-9900
Andersson received a Masters in Science in Engineering and a Ph.D. in Management from Link?ping Institute of Technology, Sweden.

Management Efficiency

The company has return on total asset (ROA) of 0.05 % which means that it generated profit of $0.05 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.15 % meaning that it created $0.15 on every $100 dollars invested by stockholders.
The company currently holds 671.5 M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives


Svend AndersenPerrigo Company Plc
Jeffrey NeedhamPerrigo Company Plc
Kimberly WhiteVertex Pharmaceuticals Incorpor
Sandra BeatyZoetis
Louis YuPerrigo Company Plc
Sripada ChandrasekharDr Reddys Laboratories Ltd
Cartikeya ReddyDr Reddys Laboratories Ltd
Douglas BoothePerrigo Company Plc
Ian SmithVertex Pharmaceuticals Incorpor
Kristin PeckZoetis
James DillardPerrigo Company Plc
Marion McCourtRegeneron Pharmaceuticals
Paul SilvaVertex Pharmaceuticals Incorpor
Joyce LeeZoetis
Daniel PlewRegeneron Pharmaceuticals
Reshma KewalramaniVertex Pharmaceuticals Incorpor
Ronald JanishPerrigo Company Plc
Umang VohraDr Reddys Laboratories Ltd
Michael PartridgeVertex Pharmaceuticals Incorpor
Alok SonigDr Reddys Laboratories Ltd
John HendricksonPerrigo Company Plc

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Current Sentiment - PRXL

PAREXEL International Investor Sentiment

Most of Macroaxis users are at this time bullish on PAREXEL International Corp. What is your perspective on investing in PAREXEL International Corp? Are you bullish or bearish?
98% Bullish
2% Bearish

Currently Active Assets on Macroaxis

Purchased over 200 shares of
a day ago
Traded for 14.76
Purchased over 50 shares of
a day ago
Traded for 53.37
Purchased few shares of
a day ago
Traded for 270.71
Purchased over 40 shares of
a day ago
Traded for 75.81
Purchased over 20 shares of
a day ago
Traded for 147.08
See also Your Equity Center. Please also try Transaction History module to view history of all your transactions and understand their impact on performance.